STOCK TITAN

Gamida Cell to Present at the BTIG Virtual Biotechnology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Gamida Cell Ltd. (Nasdaq: GMDA) announced its participation in the BTIG Virtual Biotechnology Conference on August 10, 2021, at 3:00 p.m. ET, with a live webcast available on BTIG’s site. The company is targeting a BLA submission for omidubicel, marking a potential first approval for a cell therapy for blood cancer patients needing allogeneic bone marrow transplants in Q4 2021. Additionally, an IND submission is planned for a Phase 1/2 study of GDA-201 in lymphoma patients in the second half of 2021.

Positive
  • None.
Negative
  • None.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m. ET.

The live webcast will be available on BTIG’s conference website at the time of the event, after which it will be available through BTIG’s research access.

In the fourth quarter of 2021, Gamida Cell is targeting a BLA submission for omidubicel, the first potential approval of a cell therapy for blood cancer patients in need of an allogeneic bone marrow transplant. In the second half of 2021, the Company is planning an IND submission to support the initiation of a Phase 1/2 clinical study of cryopreserved, off-the-shelf GDA-201 in patients with follicular and diffuse large b-cell lymphomas.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to anticipated regulatory submissions, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 9, 2021, as amended, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Gamida Cell as of the date of this release.

FAQ

What is Gamida Cell's participation in the BTIG Virtual Biotechnology Conference?

Gamida Cell will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 10, 2021, at 3:00 p.m. ET.

When is Gamida Cell planning to submit a BLA for omidubicel?

Gamida Cell is targeting a BLA submission for omidubicel in the fourth quarter of 2021.

What clinical study is Gamida Cell planning to initiate in 2021?

Gamida Cell plans an IND submission to start a Phase 1/2 clinical study of GDA-201 in lymphoma patients in the second half of 2021.

Where can I watch Gamida Cell's presentation from the BTIG Conference?

The live webcast of Gamida Cell's presentation will be available on BTIG’s conference website during the event.

Gamida Cell Ltd.

NASDAQ:GMDA

GMDA Rankings

GMDA Latest News

GMDA Stock Data

4.34M
120.38M
11.58%
26.49%
7.53%
Biotechnology
Healthcare
Link
Israel
Jerusalem